Endometriosis UK Annual Report for year ended 31 March 2024 

## **Endometriosis UK** 

**Annual report and financial statements for the year ended 31 March 2024** 

**Company no. 02912853** 

**Charity no. 1035810 OSCR no. SC051651** 

1 



Endometriosis UK Annual Report for year ended 31 March 2024 

## **Contents** 

## **For the year ended 31 March 2024** 

This Trustee and Directors’ report provides an overview of performance in relation to our key objectives and of future plans. It includes key performance data and the stories of some of those Endometriosis UK has helped, in addition to financial summaries and analysis. 

||Page|
|---|---|
|Reference and administrative information|3|
|Trustees’ annual report|5|
|Independent auditor’s report|26|
|Statement of financial activities (incorporating an income and expenditure account)|30|
|Balance sheet|31|
|Statement of cash flows|32|
|Notes to the Financial Statements|33|



2 



Endometriosis UK Annual Report for year ended 31 March 2024 

## **Reference and administrative information** 

## **For the year ended 31 March 2024** 

Endometriosis UK is a company limited by guarantee and a registered charity. 

Company number 02912853 Country of incorporation United Kingdom Country of registration England & Wales Charity Number 1035810 Country of registration Scotland Charity Number SC051651 

Registered office and operational address 10 – 18 Union Street, London SE1 1SZ 

**Trustees** Trustees, who are also directors under company law, who served during the year and up to the date of this report were as follows: 

Liz Campbell **Chair** Tracey Hammonds **Treasurer** Sarah Atkinson (until November 2023) Sanchia Alasia Jenny Bullis (from November 2023) Nick Burke (from November 2023) Anne Connolly (from November 2023) Anna Cooper Andy Glyde (until November 2023) Andrew Horne Sera Miller (until November 2023) Catherine Nestor (from November 2023) Emma Prach (from November 2023) Dr Veena Rao (until November 2023) Cassia Rowland Arvind Vashisht 

Endometriosis UK has a skills-based Board of Trustees, and Trustees are recruited in order to ensure that the Board has the right mix of skills and knowledge to provide effective governance. The Board of Trustees has a range of skills and experience including voluntary sector management, fundraising, financial management, primary and secondary health care and of living with endometriosis. Trustees are appointed for a term of three years which is renewable once.  Trustees may serve a maximum of six years on the Board. 

**Company Secretary** Emma Cox, CEO Endometriosis UK **Key management personnel** Emma Cox, Chief Executive **Bankers** CAF Bank Limited PO Box 289 Kings Hill West Malling Kent ME19 4TA 

3 



Endometriosis UK Annual Report for year ended 31 March 2024 

**Solicitors** BDB Pitmans LLP One Bartholomew Close London EC1A 7BL **Auditor** Sayer Vincent LLP Chartered Accountants and Statutory Auditor 110 Golden Lane London   EC1Y 0TG 

## **Medical Advisory Panel** 

Kirana Arambage, Consultant Gynaecologist, John Radcliffe Hospital, Oxford 

Professor Christian Becker, Senior Clinical Research Fellow, John Radcliffe Hospital, Oxford 

Liz Bruen, Endometriosis Specialist Nurse, Cardiff and Vale University Health Board 

Dr Sharon Dixon, GP and NIHR Doctoral Research Fellow and General Practitioner, Oxford University Emma Evans, Clinical Psychologist, University of Oxford 

Professor Andrew Horne, Professor of Gynaecology and Reproductive Sciences, Edinburgh University Shaheen Khazali, Consultant Gynaecologist and Endopelvic surgeon, HCA The Lister Hospital, Chelsea 

Dr Uma Marthi, General Practitioner with special interest in women’s health, Rochdale 

Dr Veena Rao, General Practitioner with special interest in women’s health, Cumbria 

Fevzi Shakir, Consultant Gynaecologist, Royal Free Hospital 

Claudia Tye, Endometriosis Specialist Nurse, Guys and St Thomas 

Arvind Vashisht, Consultant Gynaecologist, University College London Hospital 

Dr Katy Vincent, Associate Professor, Senior Fellow in Pain in Women, John Radcliffe Hospital, Oxford 

Our Medical Advisory Panel provides expert advice and guidance on all our work relating to medical information. A very big thank you for their hard work and dedication in supporting the endometriosis community. 

The Trustees present their report and the audited financial statements for the year ended 31 March 2024. 

Reference and administrative information set out on pages 3 and 4 forms part of this report. The financial statements comply with current statutory requirements, the memorandum and articles of association, the requirements of a directors’ report as required under company law, and the Statement of Recommended Practice - Accounting and Reporting by Charities: SORP applicable to charities preparing their accounts in accordance with FRS 102. 

4 



Endometriosis UK Annual Report for year ended 31 March 2024 

## **About endometriosis** 

Endometriosis is a disease where cells similar to those lining the womb (the endometrium) grow elsewhere in the body, most commonly within the pelvic cavity. These cells respond to the hormonal menstrual cycle, and can cause inflammation, pain and scar tissue (adhesions). Whilst often referred to as a gynaecological condition and relating to the hormonal menstrual cycle, endometriosis can be found outside the pelvic cavity. Limited research means little is known about extra-pelvic endometriosis; it’s thought to affect less than 12% of those with endometriosis, and is most commonly found on the diaphragm or in the thoracic cavity (the chest and lungs). 

An estimated 1.5 million women and those assigned female at birth in the UK have endometriosis - that’s 1 in 10 from puberty to menopause who suffer from this disease - although the impact may be felt for life.  Whilst for some symptoms are mild, for others it can be severely disabling. We currently do not know what causes the disease and there is no cure. 

Endometriosis can result in inflammation, scar tissue, severe pelvic pain, painful sexual intercourse, bowel problems, bladder problems, difficulty getting pregnant, fatigue, and a range of other issues. Symptoms vary depending on where the endometriosis is growing, and are not exclusive to endometriosis. Diagnosis can take a long time often with multiple visits to healthcare practitioners before symptoms are recognised. All too frequently the severe pain and symptoms are normalised, and those with endometriosis are left in the dark about their condition and without access to treatments. Endometriosis UK's own patient surveys have found that on average it takes 8 years 10 months from first presenting with symptoms to being diagnosed (March 2024). This figure has increased from an average of 8 years in early 2020, before the pandemic, and is unacceptably long. Between March and August 2023, we gathered data from 5,500 people, and discovered that a worrying 78% of respondents who had received a diagnosis of endometriosis had experienced one or more doctor telling them they were making a ‘fuss about nothing’ or similar comments, and many had the severity of their symptoms questioned by healthcare practitioners. The number of people reporting this experience has increased from 69% in our 2020 survey. 

Currently surgery with biopsy is considered the definitive way of diagnosing endometriosis, although there are advances in medical imaging (ultrasound and MRI) that enable skilled and trained healthcare practitioners to identify potential endometriosis – however a negative scan does not rule out endometriosis. 

There is no wholly satisfactory drug therapy and often the treatment is surgery, although for many this has to be repeated. The repercussions of endometriosis may be enormous: it can affect every aspect of life, from work and relationships to ability to conceive and overall quality of life. Since the condition is hard to see and can take a long time to diagnose, it can feel very isolating - coping with persistent pain, infertility, and other unpleasant symptoms, which are often not believed by others, and may lead to depression. 

Endometriosis can also impact partners, family members and personal relationships, and all those affected may need support. This is evident from the number of partners and family members who contact the charity. Although in the past it was considered a disease of the over 30s, increasing numbers are reporting that they are experiencing troublesome symptoms as early as puberty. There is no evidence to suggest that this is due to an increase in occurrence of endometriosis, but rather is due to the realisation at an earlier age that severe period pain is not normal. Hence help is being sought at an earlier age - something for which the charity's campaigns over many years should take credit. However, without improved diagnosis and treatment the negative outcomes of persistent pain, debilitating symptoms and potential infertility still remain. 

5 



Endometriosis UK Annual Report for year ended 31 March 2024 

## **Foreword** 

For over 40 years, Endometriosis UK has been at the forefront of demanding and achieving change for the 1.5 million women and those assigned female at birth with endometriosis in the UK, as well as providing vital support and information when people need us most. The last year was no exception, and we’re proud to share with you what has been achieved thanks to the incredible support of our volunteers, medical advisors, fundraisers, partners, staff, and supporters. 

We unfortunately continue to see the long-term repercussions of Covid-19, combined with the lack of priority afforded to menstrual health in the NHS. Gynaecology waiting lists increased by a higher percentage than any other speciality during the pandemic, and this worrying trend is continuing. Our report, _“Dismissed, ignored and belittled”- the long road to endometriosis diagnosis in the UK,_ highlighted that getting a diagnosis of endometriosis in 2024 takes an average of 8 years 10 months, up from to 8 years in 2020.  There are also stark inequalities faced by those from marginalised communities in accessing care, which everyone at Endometriosis UK is determined to turn around. Over the last year, we’ve worked with those from marginalised communities to understand the additional barriers faced in accessing care, and how we can tackle these. 

Clearly, we still have a lot of work to do and are determined to be bold in our campaigning for much needed change. New opportunities are arising that will enable us to drive our message home, both from our own research and work, and increasingly from NHS and related bodies. NICE (National Institute for Health and Care Excellence), are near to completing a partial review of their Guideline on Endometriosis, and NCEPOD (National Confidential Enquiry into Patient Outcome and Death) have undertaken a review of the quality of care for those with endometriosis, recently launching their report _Endometriosis: A Long and Painful Road_ . We’re proud that Emma Cox, our CEO, was invited to take part in both reviews. 

Our research shows that over 30% of those with endometriosis first went to see a doctor about symptoms when they were 16 or under, and with hindsight 50% think they had symptoms at 16 or under. As well as firmly knocking on the head the myth that ‘you can’t get endometriosis when you’re young’, it highlights the need to support adolescents and teens to get a diagnosis and help them access care. We partnered with Menstrual Cycle Support to develop an online course for teens on menstrual health, to support understanding of the menstrual cycle and help teenagers understand what’s ‘normal’ and how and when to seek help. We believe this will be a key tool in helping diagnosis in a constructive and supportive way, including via schools and general practice. 

Over the next year, we will continue to campaign for change so everyone with endometriosis has a prompt diagnosis and high-quality care, and funding for more research to improve care options. This includes campaigning for NHS organisations across the UK to implement the NICE guidelines, including the soon to be updated section on diagnosis, ending the postcode lottery of treatment and care, providing a baseline across the UK. Not only will this help reduce suffering for those with endometriosis, but we also believe streamlining diagnosis will save the NHS time and money. The new Labour Government stated in their manifesto “Never again will women’s health be neglected. Labour will prioritise women’s health as we reform the NHS”. We will be holding them to account on this. 

We have continued to recruit and train incredible volunteers, who generously give their time despite their own experiences of living with endometriosis, with 90 new volunteers trained across the year, increasing our total number of active volunteers to 252. We’ve run a series of successful webinars on a variety of topics including endometriosis and sex, getting the most out of a GP appointment, and managing pain, with a total of over 11,400 views. Following research into needs, we’ve produced resources on endometriosis surgery including a video, and continue to survey for information needs to identify gaps we can fill. 

6 



Endometriosis UK Annual Report for year ended 31 March 2024 

Thank you to our incredible fundraisers who have taken part in an amazing array of challenges over the last 12 months – from sky dives, rowing across the Atlantic and Walking for Endo, to tea parties and wearing yellow in the workplace. All money raised goes towards helping us continue to be there for and raise the voices of everyone affected by endometriosis, and our work would not be possible without your generosity. 

It is vital that employers provide support for employees with endometriosis in the workplace and are aware of the impact it can have on an individuals’ work life. Our Endometriosis Friendly Employer Scheme has continued to grow, with over 100 employers signed up to the scheme. Through the scheme, these workplaces are taking action to ensure employees with endometriosis and menstrual health conditions are supported and enabled to thrive at work. We were delighted employers as diverse as British Airways, East Ayrshire Council, Hargreaves Lansdown, and Westport Veterinary Clinic signed up to the scheme in the last year. Following feedback from especially small employers without dedicated HR functions, this year we also launched a Menstrual Wellbeing in the Workplace project, covering a range of menstrual health conditions as well as endometriosis. As we evaluate this project, we are reviewing to see what more we can do to support employers to support their employees. 

Historically, there has been limited research into endometriosis. We’re starting to see more, although still not enough. Endometriosis UK continues to support research and researchers, and is pleased to have representatives on all main endometriosis research projects. As well as campaigning for more money to be invested in research, we are actively involved in trying to shape the research agenda through leading effective Patient and Public Involvement (PPI). 

We’d like to end our introduction by thanking our incredible supporters for what you’ve helped us achieve this year. With new research on the horizon and a strategy in place that aims to deliver real change, we hope you’ll stand with us during the year ahead. 

Liz Campbell (Chair) Emma Cox (CEO) 

7 



Endometriosis UK Annual Report for year ended 31 March 2024 

## **Objectives and activities** 

## **Purposes and aims** 

The aim of the annual report is to review the charity’s aims, objectives, and activities each year, and share with our supporters what you have helped us achieve. We’re incredibly proud of everything we have achieved but know there is much more to do. 

The Trustees report the success of each key activity and the benefits the charity has brought to those groups of people that it is set up to help. The review also helps the Trustees ensure the charity's aims, objectives and activities remain focused on its stated purposes. 

The Trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning its future activities. In particular, the Trustees consider how planned activities will contribute to the aims and objectives that have been set. 

The charity's key activities and who it tries to help are described below. All its charitable activities are undertaken to further Endometriosis UK’s charitable purposes for the public benefit, and focus on: 

- Support for everyone living with endometriosis 

- Information and supporting research 

- Raising awareness and campaigning 

- Resourcing the organisation so that we can deliver more 

The current strategy is focussed on achieving the following outcomes for people living with endometriosis: 

- Reducing diagnosis time 

- Improving access to high quality treatment 

- Ensuring everyone with endometriosis has the support they need 

## **Achievements and performance** 

The charity's main activities and who it tries to help are described below. All its charitable activities focus on supporting people living with endometriosis and are undertaken to further Endometriosis UK’s charitable purposes for the public benefit. 

8 



Endometriosis UK Annual Report for year ended 31 March 2024 

## **Key achievements** 

## **Support for those living with endometriosis** 

## **Delivering support** 

Our volunteer-led support services continue to be a core part of how we support the endometriosis community. The team enabled Endometriosis UK volunteers to deliver face-to-face, online, and phone support to 9,594 people in this year. Our support team have trained 90 new volunteers bringing our total number of active volunteers to 252. We have welcomed our first Welsh Development Coordinator this year who continues to develop supportive services across Wales, including recruiting new volunteers and setting up new groups. 

During the year, we built on our Equality, Diversity and Inclusion (EDI) work, recruiting a Community Engagement and Involvement Officer to build relationships with grassroots, community and faith-based groups. We have launched an EDI Forum consisting of a diverse range of volunteers to help bring inclusive practices into the organisation. 

All volunteers, as well as staff, are required to adhere to Endometriosis UK’s safeguarding policy, which aims to protect vulnerable people across all aspects of our work. 

## Highlights of the last year include: 

- 262 individual support group meetings held 

- 866 support group attendees 

- 10 new support groups set up bringing our total to 61 in March 2024 

- 1,853 calls to our Helpline 

- 372 webchat conversations 

- 37,644 active members of the Health Unlocked forum 

- 20,021 views on the ‘Get Support’ and ‘support Group’ pages of our website 

- Our Living with Endometriosis events in London and Glasgow both had over 100 attendees 

- 11 webinars delivered with 1613 live views and 9,822 on YouTube 

_“Thank you for the webinar, I have learned more and am looking forward to the next one!”_ 

## **Supporting our volunteers** 

This year, we supported all our 252 active volunteers. One volunteer said: 

_"The support we get is fantastic, I know I can approach the volunteer support team with anything"_ 

We recruited and delivered induction training to new volunteers. We also designed and delivered bespoke Equality, Diversity, and Inclusion training to all our volunteers. 

## One trainee quoted: 

_“It was great hearing about the experience of others in accessing care and information. Seems to differ across the UK.  Learning about the importance of boundaries and how to manage time without burning out.”_ 

In May we ran our annual volunteer experience survey. 85% rated their experience as good or excellent compared to 73% in 2021/22. 

9 



Endometriosis UK Annual Report for year ended 31 March 2024 

Future Plans: 

- Delivery of a specialist nurse-led helpline to provide support and advice to the endometriosis community 

- Improving our volunteer training package by developing e-learning packages 

- Developing our support offer to all volunteers 

## **Information** 

Our Endometriosis Friendly Employer Scheme (EFE) offers a way for employers to confirm their commitment to developing a work environment and culture that enables employees with endometriosis to thrive at work. 

We now have over a hundred EFE members, including some major employers and household names such as British Airways, Hargreaves Lansdown, Nationwide Building Society, NHS Ayrshire and Arran, Powys County Council, Southern Water, The University of Manchester, and many more. 

We developed the EFE scheme in response to all the feedback we get on the impact of endometriosis at work. To further provide support in this important area, maximising the potential of the scheme and developing our work with employers, towards the end of the financial year, we appointed an Endometriosis Friendly Employer Scheme Manager. We look forward to further developing the scheme, reaching more employers and supporting more employees with endometriosis. 

In addition to our EFE work, we were delighted to receive funding from the Department of Health and Social Care for a two year project on Workplace Menstrual Wellbeing. This work is targeted at small and medium sized employers (SMEs), who may not have HR teams and may not be aware of menstrual health conditions. Over the year we have made significant strides, conducting a series of webinars and an in-person event aimed at educating SMEs about various menstrual health conditions including endometriosis, and providing insights 

10 



Endometriosis UK Annual Report for year ended 31 March 2024 

into how employers can create more supportive work environments for individuals affected by these conditions. We have actively participated in numerous external discussions and events focused on improving workplace conditions. 

Looking ahead, we are planning for the long-term sustainability of the project and its future trajectory. It is evident that there is a crucial need to prioritise menstrual health in the workplace, and we are committed to maintaining and nurturing this discourse. Our goal is to provide ongoing support to both employers and employees. 

Supporting those in education with endometriosis is also vital. Having previously successfully campaigned to get Menstrual Health included in the school curriculum in England, we wanted to progress our work in this area by providing a support for teenagers to help them understand their menstrual cycle. We identified a need for a resource for teens to help them understand their menstrual cycle and if what they were experiencing was ‘normal’, and to support discussion with nurses or doctors. We were delighted to partner with Menstrual Cycle Support to develop a free online course for teenagers, based on their adult course which is available on social prescribing through all healthcare practitioners. The Teen course was launched in Parliament in March 2024. In the future we will be working with Menstrual Cycle Support to encourage take up of this free resource, including awareness by healthcare practitioners and teachers to support their pupils. 

Future plans: 

- Development of our Endometriosis Friendly Employer scheme and Workplace Menstrual Wellbeing activities to reach more employers and support more employees with endometriosis. 

- Planning for the long-term sustainability of our Workplace Menstrual Wellbeing work following the initial two years of funding. 

- Increasing awareness and take up of the Menstrual Cycle Support course for teens. 

## **Providing high quality and up to date information** 

This year we have updated existing information and released new versions of Understanding Endometriosis, Endometriosis of the Bladder, Endometriosis of the Bowel, and Diagnosing Endometriosis. We have reviewed and updated our Endometriosis and couples' information to address heteronormative aspects and created a new inclusive version. We have developed tailored resources to support our volunteers understanding of endometriosis. 

We continue to work towards the Patient Information Forum TICK accreditation and have embedded those principles into our new Information Production Process. 

We identified that there was a need for up-to date, accurate and high-quality patient information on surgery for endometriosis. Our consultation reported 62% of those with endometriosis did not get enough information on surgery from the health professionals involved in their care.  Our project produced 2 leaflets on surgery for endometriosis, a video explaining the surgery journey and a Q and A webinar.  The video received 3,500 views on YouTube in its first three months. One viewer commented: 

_“I wish I’d had this before surgery – please watch if you have a lap coming up!”_ 

11 



Endometriosis UK Annual Report for year ended 31 March 2024 

Future plans 

- Launch online tools to assist those with suspected endometriosis and enable discussion with GPs. These tools will also aid GP awareness of endometriosis, and the diagnostic pathway. 

- Develop more information materials for those with endometriosis from underrepresented groups. 

- Undertake an accessibility review on all our health information to ensure that everyone can access the support and information they need. 

- Develop new information targeting adolescents and teens to allow them to know the signs and symptoms of endometriosis in a non-threatening and age-appropriate way. 

## **Research** 

We are pleased to be involved in a range of research projects. Research into endometriosis is vital to find out more about the disease. Only through research will we find out more about the cause of endometriosis, how to better treat and manage it, the support people might need, and, one day, a cure. We have partnered with university researchers and clinical trials teams to aid recruitment and participation in a number of research projects aimed at improving the lives of those living with endometriosis. 

During the year, we provided support for a range of research applications. For some we are co-investigators on the projects, ensuring the voice of those with endometriosis is at the heart of the research being developed. We have provided advice, undertaken surveys, reviewed materials and written letters of support for a number of applications, some of which take several months to hear an outcome. It has been a challenging time for clinical trials and medical research into endometriosis, with the long delays and waiting times for appointments and surgery impacting on activities that can take place. Sadly, the DIAMOND trial - aiming to 

12 



Endometriosis UK Annual Report for year ended 31 March 2024 

compare surgery with hormone treatment for those with deep endometriosis - was a casualty of this, and was closed down due to difficulties in recruitment. We continue to work closely with other research teams to support their activities and recruitment. 

Undertaking our own research has enabled us to identify issues facing the endometriosis community, and plan activities and campaigns to achieve change. Our survey of experiences of diagnosis, building on similar survey we’d undertaken in Jan/Feb 2020 and allowing direct comparison from before and after the pandemic, received 4,000 responses. This survey and analysis of results formed the basis of our _“Dismissed, ignored and belittled’_ report for Endometriosis Action Month in March. 

## Future plans: 

- Continue to provide PPI (Patient and Public Involvement) support for research 

- Campaign for more investment in much needed research. 

- Develop the research section on our website to provide more information about research, including how to get involved. 

- Identify gaps in knowledge and opportunities to undertake our own research, for example on experiences of diagnosis, treatment and care. 

## **Awareness and campaigning** 

Awareness and campaigning are key activities to underpin our support services, information provision and research. We have continued work to improve the lives of those affected by endometriosis through our campaigning and awareness raising activities. This has included responding to policy consultations, building relationships with politicians across the UK, improving our social media presence to reach new audiences, working with national media, and by creating e-action campaigns that has resulted in over 500 supporters writing to their elected representatives to call for change. 

Gathering evidence is key to driving change. This year we were proud to launch a highly impactful report, “Dismissed, ignored and belittled: a long road to endometriosis diagnosis in the UK”, that showed getting a diagnosis for endometriosis now takes almost a year longer than before the pandemic; averaging 8 years and 10 months in the UK in 2024 compared to 8 years in 2020. The report was used as a catalyst to call for change, as we called on decision makers across the UK to take action to reduce diagnosis times and improve access to treatment, and secured high profile media coverage across local and national media outlets. 

Our policy work has also seen us work effectively with MSPs in Scotland on the implementation of the Women’s Health Plan, and in Westminster there has been ongoing work with Government Officials in the Department of Health and Social Care who are working to deliver the UK’s Women’s Health Strategy.  In Wales, we continue to be part of the Women’s Health Coalition inputting into the Welsh Government Women’s Health Plan, including by submitting a joint response to the Welsh Government’s Chronic Conditions consultation. 

We also continue to provide Secretariat to the All-Party-Parliamentary-Group (APPG) on Endometriosis in Westminster, and the Cross-Party Group (CPG) on Women’s Health in Scotland, and worked to brief politicians and Peers on key issues affecting those with endometriosis – including on health, education and employment. 

Responding to policy consultations also remains a key part of our influencing work. We have responded to numerous consultations including the Prioritisation of Women & Reproductive Health Guidelines, guidelines on the diagnosis and management of endometriosis, and consultations on the commissioning of new medications. 

13 



Endometriosis UK Annual Report for year ended 31 March 2024 

Having long lobbied Governments on the need for more awareness about endometriosis, we were pleased to see improved information on endometriosis on NHS websites across the UK. NHS Inform (Scotland) continues to develop its section on periods and menstrual health, including endometriosis. We were delighted to work with NHS England digital team to provide information and case studies to support their development of public awareness resources including videos on endometriosis. A new website, Endometriosis Cymru, was commissioned by NHS Wales to help reduce diagnosis times and help access to treatment. 

Our campaigning work has also seen the launch of ‘Drop the Benign’, a social media campaign in partnership with the Royal College of Obstetricians and Gynaecologists (RCOG).  The campaign called on health practitioners to stop using the word 'benign' - when referring to endometriosis, and other gynaecological conditions.  As a result, the campaign successfully reached a range of health practitioners working in the field of women’s health. 

Our social media channels continue to grow, with increased engagement and following across all our platforms. Our following has increased across all our platforms, and we have a combined following across all our channels of 156,330, compared to 142,976 the previous year. A particular social media highlight was relaunching our Tik Tok Channel, which has allowed us to reach a new and younger audience. This is key to raising awareness of endometriosis and its symptoms amongst young people – empowering those experiencing symptoms to seek help. 

We are incredibly grateful to those with endometriosis who have bravely shared their story with the media, and in total this year there has been 377 pieces of news coverage on endometriosis in the UK across broadcast and print outlets. 

Endometriosis Action Month remains a key date in the calendar for Endometriosis UK and the endometriosis community, as the community comes together to raise awareness of endometriosis and demand change. This year was no exception, with the theme: “Could it be endometriosis?” raising vital awareness of the symptoms of endometriosis amongst the general public and decision makers. We were proud to host virtual and in person events in all 4 nations of the UK. 

14 



Endometriosis UK Annual Report for year ended 31 March 2024 

Future plans 

- Establish links with relevant Ministers, key government officials and MPs to influence change after the UK General Election. 

- Raise awareness of the main symptoms and impact of endometriosis through our work with the media. 

- Work with decision makers and stakeholders across the UK to influence change. 

- Continue to ensure those affected by endometriosis are at the heart of our campaigning work; offering new and exciting opportunities for our community to engage with their elected representatives to influence change. 

- Deliver a successful Action Month in 2025; engaging the endometriosis community and decision makers to raise awareness and demand change. 

## **Resourcing** 

We’ve continued to work to deliver our 5-year strategic plan, strengthening our ambitions and resolve to ensure everyone living with endometriosis has a prompt diagnosis, high quality care and the support they need. 

Our staff team grew further this year, with new permanent roles allowing us to increase the amount of work we can do. As new staff settle in, we look forward to being able to deliver more for the endometriosis community in the year ahead. 

We have continued to diversify our income and have had another great year for Community Fundraising, Trusts and Grant donations and Individual Giving. We were delighted to receive support from a number of funders and partners including Garfield Weston, SENSE Foundation Brussels, The Scottish Government, The National Lottery, Bloomberg, and Time of the Month (TOTM). This support has contributed to the running of our much-needed support services, including volunteer training and resources, our information provision and awareness raising activities. 

15 



Endometriosis UK Annual Report for year ended 31 March 2024 

## Future Plans 

- Develop our new 5-year organisational strategy, to start in 2025. 

- Continued investment in volunteer training, support and development. 

- Investing in a new Specialist nurse-led helpline to provide support and advice to the endometriosis community. 

- Grow and develop the Endometriosis Friendly Employer Scheme ensuring those with endometriosis can thrive in the workplace. 

- Continue to develop and grow our partnerships with funding bodies, charitable trusts & companies. 

- • Strengthen and grow our public fundraising which includes individual donations, community fundraising and fundraising challenges. 

## **Supporters** 

We fundraise in diverse ways alongside raising as much awareness as possible, our main fundraising activities include: 

- Sponsored Challenge Events. 

- Our flagship Fundraising Challenges including Walk for Endo and Go Yellow! 

- Supporting fundraisers with their own fundraising events e.g. bake sales. 

- Applications to Trusts, Foundations and Grant Giving organisations. 

- Email marketing to supporters who have opted in to receive fundraising news and appeals. 

- Social media campaigns. 

- Working with carefully selected companies through Commercial Participator Agreements when necessary. 

We are incredibly grateful to our community of supporters who make our work possible. Almost 1,000 people participated in our flagship challenges Walk for Endo, Winter Walk for Endo, Go Yellow!, Tea for Endo, and the 1in10 Challenge, raising over £140,000. Action Month saw a real boost in workplace fundraising which is great for awareness raising, breaking taboos and tackling stigma. In addition to these events, many others fundraised for us by participating in their own events or found new and creative ways to fundraise. Highlights include a group of men doing a million KG Challenge, the _There She Rows_ group who rowed across the Atlantic, and a group of dedicated endometriosis consultants and trainees who cycled from London to Edinburgh in aid of Endometriosis UK. 

It was also a fantastic year for Challenge Event Fundraising with over £120,000 raised by over 300 participants in a huge programme of events. We had places in the Great North Run, Asics 10k, Royal Parks Half Marathon, 

16 



Endometriosis UK Annual Report for year ended 31 March 2024 

Cardiff Half Marathon, London Landmarks Half Marathon, Brighton Marathon, Edinburgh Marathon, and many more. Despite only having one charity space for the London Marathon, we had 19 people with open ballot spaces choosing to run for us including James Phelps of Harry Potter fame, which was great for extra awareness raising. 

In October we participated in The Big Give Women and Girls Match Funding Campaign and were delighted to have exceeded our target of £20,000. The campaign was focused on supporting and training our amazing volunteers to run our vital support services, and we were grateful to all who donated . 

As a supporter-focused charity, we understand that all our achievements to support those impacted by endometriosis would not be possible without the generosity of our amazing supporters. We are committed to fundraising in an honest and transparent way. We are registered with the Fundraising Regulator and pay an annual levy to support its work. We adhere to the Code of Fundraising Practice and our supporter promise remains at the heart of all our fundraising. When fundraising for Endometriosis UK you can be sure that we: 

- **Are clear, honest and open-** we tell the truth and do not exaggerate. 

- **We are respectful-** we treat our supporters respectfully and respect your rights and privacy. Your data is safe with us, we will never sell or share your data to a third-party organisation. We will never bombard supporters or put anyone under pressure to donate. 

- **We are fair and reasonable-** we take care not to use any images or words that intentionally cause distress or anxiety. 

- **We are accountable and responsible-** we will never knowingly solicit donations from vulnerable people. We do all we can to ensure that our supporters comply with fundraising regulations and this promise. 

At Endometriosis UK we have not engaged any professional fundraisers to raise funds on behalf. The charity established commercial participator agreements with all sole traders and businesses known to be fundraising for Endometriosis UK and monitored the activities of those fundraising by reviewing proposed messaging and products, and social media monitoring. There were no known failures to comply with the code of the Fundraising Regulator, and no complaints were received regarding staff, volunteers or individuals fundraising for Endometriosis UK. Our fundraising activities are closely monitored by the Finance Committee, which reports to our Board of Trustees. 


**----- Start of picture text -----**<br>
ee piled<br>**----- End of picture text -----**<br>


17 



Endometriosis UK Annual Report for year ended 31 March 2024 

Future plans 

- Increase participation in events and opportunities to engage with and support us. 

- Deliver a varied and exciting year-round calendar of fundraising events. 

- Offer more non-physical fundraising challenges. 

- Continue to offer to excellent stewardship to all our supporters. 

- Support more workplaces to fundraise and raise awareness. 

## **Beneficiaries of our services** 

Our beneficiaries include all those with or impacted by endometriosis. 

Endometriosis UK is committed to supporting and advocating for everyone affected by endometriosis regardless of race, gender, sex, gender identity, class, sexual orientation or disability and ensuring diversity. Everyone affected by endometriosis needs to be acknowledged, and we know that we must do more to identify the needs of all those affected by endometriosis, develop, maintain, and evaluate our work to meet those needs and advocate for necessary change and ensure all voices are heard. We know that there are additional complexities in accessing healthcare and support for those from Black, Asian and minority ethnic communities, and for the LGBTQ+ community. 

We are taking steps to actively ensure we drive change for those from under-represented groups. The Board’s Diversity & Inclusion Group continues to take this work forward. We have recruited a Community and Involvement Officer to build relationships and seek out partnerships with grassroots, community and faithbased groups. We have also developed an EDI Forum, recruiting from a diverse group of volunteers to act as critical friends to the organisation. 

## **Finances and Governance** 

## **Financial review** 

The Trustee Board oversees the charity’s finances. To support the Board, a Finance Committee meets regularly, chaired by our Treasurer. 

For the financial year 2023/24 we planned a significant increase in our expenditure so that we could improve support to the endometriosis community and have a louder voice for the community. We were able to do this due to increasing income over prior years and building our reserves, enabling sustainable expansion. Expenditure increased to £1,166,034 in 2023/24, up from £787,521 in 2022/2023. Planned investment was undertaken focusing on where we identified most long-term impact for our beneficiaries, notably around helpline and support services, and information services. A planned increase in staff had been staggered over 2021/22 year, with full year staff costs for the first time in 2023/24. 

Expenditure is regularly reviewed and carefully monitored. Investments included developing a Workplace Menstrual Wellbeing project and raising funds to increase support and activity in Wales allowing us to recruit our first staff member in Wales in summer 2023. With increasing staff, we slightly expanded our office space within the Royal College of Obstetricians and Gynaecologists building. At the Royal College we are part of a hub for women’s health charities enabling us to work collaboratively more easily with the Royal College and other charities with similar interests. Further expansion of our work is planned over the next year, including development of our information provision, expanding our support network, and increasing our campaigning and awareness work. Despite the increase in expenditure we generated a surplus of £53,693 (2023: £107,049) due to the amazing fundraising from our supporters and the increased skill of our fundraising staff team. 

Income increased significantly this year from £894,570 in 2022/2023 to £1,219,727 in 2023/2024. 

18 



Endometriosis UK Annual Report for year ended 31 March 2024 

The main increases were in the following areas: 

- Tru sts and Grants, owing to new grants from Garfield Weston Foundation, The Sense Foundation Brussels, Bloomberg and The Scottish Government 

- Support from companies and workplaces 

- Donations from individuals 

- Very strong performance in Community Fundraising 

The Trustees aim to secure diverse income streams to ensure our income is sustainable and more resilient to change in the external environment. In this way we can achieve our objectives – we have ambitious plans. Through both managing costs and developing our fundraising, the Trustees carefully monitored finances over the year to ensure the year ended with unrestricted reserves that comfortably met our reviewed reserves policy. As part of our planned growth strategy, we have grown our reserves which enabled us to grow the organisation over the last 4 years in a sustainable way. Having reserves enabled us to survive the initial impact of Covid-19 and undertake managed growth through the pandemic and the more recent cost of living crisis. We want to continue to grow so we can do more to support all those with endometriosis. The Trustees working closely with the CEO will continue to look for opportunities to develop further fundraising opportunities along with how best to spend our income to deliver the most for those with endometriosis. 

## **Principal risks and uncertainties** 

The charity reviews risk on a regular basis and uses a risk-based management approach to decision making. This continued in 2023-24, covering the key aspects of our work including finance, governance and management, operational and external factors. Material risks were identified, reviewed and mitigated by the Trustees and this will continue in the year ahead.  Time was spent examining strategic risks in the external environment and reviewing the strategic plan against these. 

Our risk statement was reviewed, and our risk register updated. The risk register is reviewed on a regular basis by staff and Trustees. A range of 5-year scenarios and financial modelling was undertaken to enable the Trustees to plan how to manage the charity, monitor progress and mitigate risks. Expenditure continues to be carefully monitored given uncertainty about fundraising income in the challenging economic climate. 

Our key risks, and our mitigations for these are: 

- Not adapting to the changing environment and not meeting the needs of the endometriosis community. We must be a reliable source of valuable information and ensure it is available across different media. We proactively campaign for changes needed to improve the care and treatment, including those currently undiagnosed. Throughout the year we focused on providing needed support, through researching what was of importance to the endometriosis community and identifying gaps in our provision, planned and launched campaigns to improve access to treatment and care, and worked with healthcare practitioners and partners to provide current information. 

- Not having sufficient funds to deliver services and achieve objectives. Without growing our income, it will be more difficult to deliver our ambitious strategy. We are focusing on both improving our stewardship to support individuals that fundraise for us and continuing to diversify our income sources for example through grants and corporate partnerships. 

- Information technology – risk our systems failing to meet our operational need. IT systems are crucial to our work, and as a small charity our IT support is via external providers. We reviewed all our providers, identified and implemented new software to support our work, and upgraded our website. We have also started exploring how AI may be able to assist us in our work. 

19 



Endometriosis UK Annual Report for year ended 31 March 2024 

## **Reserves policy and going concern** 

Our reserves policy is to hold unrestricted reserves equivalent to at least 6 months’ operating costs. We hold financial reserves for practical reasons, including: 

- Ensuring we can go on funding our vital work should our income fall below target. Having reserves should give us time to adjust expenditure without causing undue disruption to our projects and those we support. 

- Providing working capital to meet upfront expenditure during the year before income is received. 

- To provide resource for investment, e.g. developing services and ensuring we maximise our reach. 

As detailed above our reserves have increased this year which will support the expansion of our work and ensure our sustainable growth. Free reserves as of 31st March 2024 were £1,071,060. This equates to 8 months of operating costs for the financial year taking account of designated funds which have been set aside for committed future projects. £97,404 of restricted funds was carried forward. We started the year in a good financial position, having worked hard over prior years to build reserves in order to expand our activities. We have cautiously expanded to ensure sustainability, with expenditure minimised whilst we ascertained the impact of inflation and cost of living challenges. The reserves level achieved is based on meeting our reserves policy over the next year as the charity grows. 

We would like to thank all of our fundraisers, donors and partners who were so generous over the year. 

The Trustees have reviewed the level of reserves and available liquid resources in the context of plans over the next 12 months, the five-year financial scenario plans and the organisational risk assessment. The Trustees believe that Endometriosis UK has sufficient financial resources to continue in operational existence for the foreseeable future and that we are well placed to manage its operating risks successfully. They have therefore continued to adopt the going concern basis of accounting in preparing the annual financial statements. 

## **Structure, governance and management** 

Endometriosis UK is a charitable company limited by guarantee, incorporated on 25th March 1994 and registered with the Charity Commission as a charity on 29th March 1994. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association. In March 2021, we registered with OSCR - the Scottish Charity Regulator. 

The Board of Trustees has 3 sub committees, Finance, Diversity and Inclusion, and Nominations.  These operate to agreed Terms of Reference and with limited delegated powers from the Board. 

The recruitment of Trustees is framed by an audit of the skills held by the members of the Board. Trustees are appointed by an open recruitment process using both search and advertisement as appropriate, against an agreed person profile and job specification.  Shortlisted candidates are interviewed by a Nominations Committee of the Board who make a recommendation to the Board.  The AGM of the Charity confirms all appointments. 

All Trustees give their time voluntarily and receive no benefits from the charity. Any expenses reclaimed from the charity are set out in note 7 to the accounts. 

## **Trustee induction and training** 

In 2023, 4 Trustees reached their six-year term of office. Following extensive advertising via social media, trustee recruitment websites and our networks, we were delighted to receive over 50 applications. Thank you to everyone who applied, we had a strong field to recruit from. Having followed the recruitment process, 5 new Trustees were appointed at the AGM in November 2023. 

20 



Endometriosis UK Annual Report for year ended 31 March 2024 

New Trustees undergo a formal induction process covering, governance, risk management, financial systems and agreed procedures. 

The Board hold an annual away day to consider strategy and review the performance of the Board. Diversity and Inclusion training was undertaken by Board members, and opportunities for training and knowledge development are raised with the Board, for example the training offered by our auditors. 

## **Risk Management** 

The Trustees have a Risk Policy and a Risk Register. Each Board Meeting assesses whether new risks have emerged or whether any of the identified risks have changed in severity.  The whole risk register was reviewed at the September and November Board meetings.  Trustees consider that the formulated plans to deal with such risks are appropriate at present. 

## **Remuneration policy for key management personnel** 

The salary of the CEO is agreed by the Board of Trustees, taking into account benchmarking across the sector, performance against objectives, and market conditions. Our work is dependent on voluntary donations and we act in an open and transparent way that respects the money, time and energy given by donors and volunteers. In our commitment to openness, we disclose information about the CEO’s salaries within our annual report, as recommended by the National Council for Voluntary Organisations (NCVO). 

## **Statement of responsibilities of the Trustees** 

The Trustees (who are also directors of Endometriosis UK for the purposes of company law) are responsible for preparing the Trustees’ annual report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). 

The law applicable to charities in England and Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to: 

- Select suitable accounting policies and then apply them consistently. 

- Observe the methods and principles in the Charities SORP. 

- Make judgements and estimates that are reasonable and prudent. 

- State whether applicable UK Accounting Standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements. 

- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation. 

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

In so far as the Trustees are aware: 

- There is no relevant audit information of which the charitable company’s auditor is unaware. 

- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information. 

21 



Endometriosis UK Annual Report for year ended 31 March 2024 

Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. At the November AGM, the members voted to agree proposed changes to the governing document of the charity, the Articles of Association, to change the legal members of the charity to be the Trustees. The Trustees have no beneficial interest in the charity. 

## **Auditor** 

Sayer Vincent LLP was re-appointed as the charitable company's auditor during the year and has expressed its willingness to continue in that capacity. 

The Directors annual report has been prepared in accordance with the special provisions applicable to companies subject to the small companies' regime. 

The Trustees’ annual report has been approved by the Trustees on 9[th] September 2024 and signed on their behalf by 

Liz Campbell (Chair) 

Tracey Hammonds (Treasurer) 

22 



Endometriosis UK Annual Report for year ended 31 March 2024 

## **Acknowledgements** 

We could not do the work we do without the time and knowledge kindly offered to us by our volunteers, fundraisers, speakers, health experts and medical advisors. Without them, we would not be able to reach and support the people we do. We would like to thank them all for their on-going support and generosity. 

All those volunteers who have given up their time to support people affected by endometriosis - through the Helpline, Support Groups, Webchat, and Health Unlocked - receive a special vote of thanks. A huge thanks as well to everyone who took on a challenge event or hosted their very own fundraising project to raise money to support the charity. 

And a very heartfelt thank you to those who told their stories to the media to raise awareness, which can be such a hard and emotional thing to do yet is vital in raising awareness and helping others. 

We are very aware of the significant inequalities faced by those from marginalised communities in accessing care. We are determined to turn this around, and thank you to the charity Cysters and founder Neelam HeeraShergill, for partnering with us and supporting us on this journey. 

As always, all of our work will be a team effort. Our staff, volunteers, members, Trustees, those with endometriosis in our wider community, their friends and family, healthcare professionals, researchers – all of those who work so tirelessly as part of Team Endometriosis are making a huge difference where it is so desperately needed. We are grateful to those organisations who have provided expertise and support to help us raise awareness. 

During the year, four of our Trustees came to the end of their maximum term of office. Thank you to Andy, Sarah, Sera, and Veena for all our hard work and support over the last 6 years. 

We are extremely grateful for the continued and new support of the funders below. We would also like to thank every individual and group who has made a donation and encouraged others to support and fundraise for us this year. We would also like to thank our small and dedicated staff team. 

- Department of Health and Social Care 

- Scottish Government 

- Bloomberg 

- Garfield Weston Foundation 

- SENSE Foundation Brussels 

- National Lottery Community Fund 

- Time of the Month (TOTM) 

- Gedeon Richter 

- The Department of Health and Social Care 

- The Whitaker Charitable Trust 

- The Edith Murphy Foundation 

- The Eddleston Settlement 

- Powell Charitable Trust 

23 



Endometriosis UK Annual Report for year ended 31 March 2024 

## **Meet the Endometriosis UK governance and staff team** 

24 



Endometriosis UK Annual Report for year ended 31 March 2024 

## **Get involved** 

The more people working together the stronger we are and the louder our voice. We have a range of ways you can get involved, for more information please check out our website: www.endometriosis-uk.org/get-involved. 

If you would like to hear what we are up to throughout the year, sign up for our regular e-update. 

## **Contact** 

Endometriosis UK 10 -18 Union Street, London SE1 1SZ Tel: 020 7222 2781 Helpline: 0808 808 2227 www.endometriosis-uk.org/contact-us 

Twitter @EndometriosisUK Instagram endometriosis.uk Facebook www.facebook.com/endometriosis.uk.org 

25 



Endometriosis UK Annual Report for year ended 31 March 2024 

## **Independent auditor’s report to the members of Endometriosis UK** 

## Opinion 

We have audited the financial statements of Endometriosis UK (the ‘charitable company’) for the year ended 31 March 2024 which comprise the statement of financial activities, balance sheet, statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 _The Financial Reporting Standard applicable in the UK and Republic of Ireland_ (United Kingdom Generally Accepted Accounting Practice). 

In our opinion, the financial statements: 

- Give a true and fair view of the state of the charitable company’s affairs as at 31 March 2024 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended 

- Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice 

- Have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) 

## Basis for opinion 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

## Conclusions relating to going concern 

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on Endometriosis UK's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. 

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. 

## Other Information 

The other information comprises the information included in the trustees’ annual report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such 

26 



Endometriosis UK Annual Report for year ended 31 March 2024 

material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 

We have nothing to report in this regard. 

## Opinions on other matters prescribed by the Companies Act 2006 

In our opinion, based on the work undertaken in the course of the audit: 

- The information given in the trustees’ annual report, for the financial year for which the financial statements are prepared is consistent with the financial statements; and 

- The trustees’ annual report, has been prepared in accordance with applicable legal requirements 

## Matters on which we are required to report by exception 

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees’ annual report. 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion: 

- Adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or 

- The financial statements are not in agreement with the accounting records and returns; or 

- Certain disclosures of trustees’ remuneration specified by law are not made; or 

- We have not received all the information and explanations we require for our audit; or 

- The directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies’ exemptions in preparing the trustees’ annual report and from the requirement to prepare a strategic report. 

## Responsibilities of trustees 

As explained more fully in the statement of trustees’ responsibilities set out in the trustees’ annual report, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. 

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so. 

## Auditor’s responsibilities for the audit of the financial statements 

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts. 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise 

27 



Endometriosis UK Annual Report for year ended 31 March 2024 

from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud are set out below. 

## Capability of the audit in detecting irregularities 

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and noncompliance with laws and regulations, our procedures included the following: 

- We enquired of management, and the audit and risk committee, which included obtaining and reviewing supporting documentation, concerning the charity’s policies and procedures relating to: 

   - Identifying, evaluating, and complying with laws and regulations and whether they were aware of any instances of non-compliance; 

   - Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected, or alleged fraud; 

   - The internal controls established to mitigate risks related to fraud or non-compliance with laws and regulations. 

- We inspected the minutes of meetings of those charged with governance. 

- We obtained an understanding of the legal and regulatory framework that the charity operates in, focusing on those laws and regulations that had a material effect on the financial statements or that had a fundamental effect on the operations of the charity from our professional and sector experience. 

- We communicated applicable laws and regulations throughout the audit team and remained alert to any indications of non-compliance throughout the audit. 

- We reviewed any reports made to regulators. 

- We reviewed the financial statement disclosures and tested these to supporting documentation to assess compliance with applicable laws and regulations. 

- We performed analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud. 

- In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments, assessed whether the judgements made in making accounting estimates are indicative of a potential bias and tested significant transactions that are unusual or those outside the normal course of business. 

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation.  This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. 

A further description of our responsibilities is available on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities _._ This description forms part of our auditor’s report. 

28 



Endometriosis UK Annual Report for year ended 31 March 2024 

## Use of our report 

This report is made solely to the charitable company's members as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed. 

Fleur Holden (Senior statutory auditor) 

## 29 November 2024 

for and on behalf of Sayer Vincent LLP, Statutory Auditor 

110 Golden Lane, LONDON, EC1Y 0TG 

Sayer Vincent LLP is eligible to act as auditor in terms of section 1212 of the Companies Act 2006 

29 



## Endometriosis UK 

Statement of financial activities (incorporating an income and expenditure account) 

For the year ended 31 March 2024 

|Note<br>Income from:<br>2<br>Income from charitable activities<br>3<br>4<br>5<br>5<br>5<br>5<br>6<br>Reconciliation of funds:<br>Helpline and support services<br>Grants and donations<br>Other trading activities<br>Charitable activities<br>Interest<br>Other<br>Total income<br>Expenditure on:<br>Raising funds<br>Net income for the year<br>Total expenditure<br>Information services<br>Research<br>Total funds carried forward<br>Net movement in funds<br>Total funds brought forward|Unrestricted<br>£<br>503,961<br>-<br>414,129<br>19,013<br>-|Restricted<br>£<br>-<br>282,624<br>-<br>-<br>-|2024<br>Total<br>£<br>503,961<br>282,624<br>414,129<br>19,013<br>-|Unrestricted<br>£<br>299,811<br>-<br>392,558<br>6,253<br>6,437|Restricted<br>£<br>-<br>189,511<br>-<br>-<br>-|2023<br>Total<br>£<br>299,811<br>189,511<br>392,558<br>6,253<br>6,437|
|---|---|---|---|---|---|---|
||937,103|282,624|1,219,727|705,059|189,511|894,570|
||192,383<br>347,738<br>312,957<br>30,569|-<br>282,386<br>-<br>-|192,383<br>630,124<br>312,957<br>30,569|171,020<br>278,736<br>168,602<br>25,056|-<br>144,108<br>-<br>-|171,020<br>422,844<br>168,602<br>25,056|
||883,648|282,386|1,166,034|643,413|144,108|787,521|
||53,455|238|53,693|61,646|45,403|107,049|
||53,455<br>1,201,605|238<br>97,166|53,693<br>1,298,771|61,646<br>1,139,959|45,403<br>51,763|107,049<br>1,191,722|
||1,255,060|97,404|1,352,464|1,201,605|97,166|1,298,771|



All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 15a to the financial statements. 

30 



Endometriosis UK 

Company no. 02912853 

## Balance sheet 

## As at 31 March 2024 

|As at 31 March 2024<br>Balance sheet|||Company no. 02912853|Company no. 02912853|
|---|---|---|---|---|
|Note<br>Fixed assets:<br>12<br>Current assets:<br>13<br>Liabilities:<br>14<br>16a<br>Total unrestricted funds<br>General reserve<br>Total charity funds<br>Cash at bank and in hand<br>Tangible assets<br>The funds of the charity:<br>Creditors: amounts falling due within one year<br>Net current assets<br>Total net assets<br>Restricted funds<br>Unrestricted funds:<br>Designated funds<br>Total assets less current liabilities<br>Debtors|£<br>£<br>34,417<br>34,417<br>39,705<br>1,372,826<br>1,412,531<br>(94,484)<br>1,318,047<br>1,352,464<br>1,352,464<br>97,404<br>238,000<br>1,017,060<br>1,255,060<br>1,352,464<br>2024||£<br>£<br>38,013<br>38,013<br>76,092<br>1,236,131<br>1,312,223<br>(51,465)<br>1,260,758<br>1,298,771<br>1,298,771<br>97,166<br>336,000<br>865,605<br>1,201,605<br>1,298,771<br>2023||
|||34,417<br>1,318,047||38,013<br>1,260,758|
||1,412,531<br>(94,484)||1,312,223<br>(51,465)||
||238,000<br>1,017,060||336,000<br>865,605||
|||1,352,464||1,298,771|
|||1,352,464||1,298,771|
|||97,404<br>1,255,060||97,166<br>1,201,605|
||||||
|||1,352,464||1,298,771|



Approved by the trustees on  9 September 2024 and signed on their behalf by 

Liz Campbell Director 

Tracey Hammonds Director 

31 



Endometriosis UK 

## Statement of cash flows 

## For the year ended 31 March 2024 

|Cash flows from operating activities<br>Net income for the reporting period<br>(as per the statement of financial activities)<br>Depreciation charges<br>Decrease in debtors<br>Increase in creditors<br>Net cash provided by operating activities<br>Cash and cash equivalents at the beginning of the year<br>Net cash used in investing activities<br>Cash flows from investing activities:<br>Purchase of property, plant and equipment<br>Cash and cash equivalents at the end of the year<br>Change in cash and cash equivalents in the year|£<br>£<br>53,693<br>12,543<br>36,387<br>43,019<br>145,642<br>(8,947)<br>(8,947)<br>136,695<br>1,236,131<br>1,372,826<br>2024|£<br>£<br>53,693<br>12,543<br>36,387<br>43,019<br>145,642<br>(8,947)<br>(8,947)<br>136,695<br>1,236,131<br>1,372,826<br>2024|£<br>£<br>107,049<br>7,656<br>38,484<br>17,500<br>170,689<br>(27,887)<br>(27,887)<br>142,802<br>1,093,329<br>1,236,131<br>2023|£<br>£<br>107,049<br>7,656<br>38,484<br>17,500<br>170,689<br>(27,887)<br>(27,887)<br>142,802<br>1,093,329<br>1,236,131<br>2023|
|---|---|---|---|---|
|||145,642<br>(8,947)||170,689<br>(27,887)|
||||||
|||136,695<br>1,236,131||142,802<br>1,093,329|
|||1,372,826||1,236,131|



32 



Endometriosis UK 

Notes to the financial statements 

## For the year ended 31 March 2024 

## 1 Accounting policies 

## a) Statutory information 

Endometriosis UK is a charitable company limited by guarantee and is incorporated in the UK. 

The registered office address is 10-18 Union Street, London, SE1 1SZ. 

## b) Basis of preparation 

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP FRS 102), The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. 

In accordance with the Charities SORP, the accounts of Endometriosis UK Trading Limited have not been incorporated into these accounts on the grounds that the results are not material. The profit covenanted by Endometriosis UK Trading Limited is included in other trading activities. This report therefore provides information about the standalone charity only. For information, the subsidiary company results and the investment the charity holds are shown separately in Note 10 to the financial statements 

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy or note. 

In applying the financial reporting framework, the trustees have made a number of subjective judgements, for example in respect of significant accounting estimates. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.  The nature of the estimation means the actual outcomes could differ from those estimates. Any significant estimates and judgements affecting these financial statements are detailed within the relevant accounting policy below. 

## c) Public benefit entity 

The charity meets the definition of a public benefit entity under FRS 102. 

## d) Going concern 

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.  The trustees reviewed income and expenditure and undertook a risk analysis, resulting in recasting the budget to reduce expenditure, and looking to identify and maximise income opportunities. Expenditure was managed carefully through the year, and a focus on developing new income sources has resulted in a strong income level for the year. 

## e) Income 

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the income have been met, it is probable that the income will be received and that the amount can be measured reliably. 

Income from government and other grants, whether ‘capital’ grants or ‘revenue’ grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred. 

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor’s intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is a treated as a contingent asset and disclosed if material. 

Income received in advance of the provision of a specified service is deferred until the criteria for income recognition are met. 

## f) Donations of gifts, services and facilities 

Donated professional services and donated facilities are recognised as income when the charity has control over the item or received the service, any conditions associated with the donation have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), volunteer time is not recognised so refer to the trustees’ annual report for more information about their contribution. 

On receipt, donated gifts, professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt. 

33 



Endometriosis UK 

Notes to the financial statements 

For the year ended 31 March 2024 

- 1 Accounting policies (continued) 

- g) Interest receivable 

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank. 

- h) Fund accounting 

   - Restricted funds are to be used for specific purposes as laid down by the donor.  Expenditure which meets these criteria is charged to the fund. 

Unrestricted funds are donations and other incoming resources received or generated for the charitable purposes. 

Designated funds are unrestricted funds earmarked by the trustees for particular purposes. 

## i) Expenditure and irrecoverable VAT 

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure is classified under the following activity headings: 

- Costs of raising funds relate to the costs incurred by the charity in inducing third parties to make voluntary contributions to it, as well as the cost of any activities with a fundraising purpose 

- Expenditure on charitable activities includes the costs of delivering services undertaken to further the purposes of the charity and their associated support costs, to include: 

   - Helpline and support services - providing services for the relief of endometriosis 

   - Information services - relating to advancing the education of those with the disease, the general public and health professionals regarding endometriosis 

   - Research - activities to support research into endometriosis to improve understanding, treatment and management of the disease. 

- Other expenditure represents those items not falling into any other heading 

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred. 

## j) Allocation of support costs 

Resources expended are allocated to the particular activity where the cost relates directly to that activity.  However, the cost of overall direction and administration of each activity, comprising the salary and overhead costs of the central function, is apportioned on the following basis which are an estimate, based on staff time, of the amount attributable to each activity. 

Where information about the aims, objectives and projects of the charity is provided to potential beneficiaries, the costs associated with this publicity are allocated to charitable expenditure. 

Where such information about the aims, objectives and projects of the charity is also provided to potential donors, activity costs are apportioned between fundraising and charitable activities on the basis of area of literature occupied by each activity. 

|||2024|2023|
|---|---|---|---|
||Raising funds|18%|17%|
||Helpline & Support Services|51%|55%|
||Information Services|21%|20%|
||Research|10%|8%|



Governance costs are the costs associated with the governance arrangements of the charity.  These costs are associated with constitutional and statutory requirements and include any costs associated with the strategic management of the charity’s activities. 

## k) Operating leases 

Rental charges are charged on a straight line basis over the term of the lease. 

## l) Tangible fixed assets 

Items of equipment are capitalised where the purchase price exceeds £1,000. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use. 

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows: 

- Office equipment 

## m) Debtors 

Trade and other debtors are recognised at the settlement amount due 

4 years 

34 



Endometriosis UK 

Notes to the financial statements 

## For the year ended 31 March 2024 

## 1 Accounting policies (continued) 

- n) Cash at bank and in hand 

   - Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. 

## o) Creditors and provisions 

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due. 

## p) Pensions 

The charity contributes to workplace pension schemes for its employees. Contributions are charged to the Statement of Financial Activities in the period to which they relate. 

## 2 Income from grants and donations 

|Income from grants and donations|||||||
|---|---|---|---|---|---|---|
|Endometriosis UK Trading Ltd<br>Other donations<br>Legacy donations<br>Gift In Kind|Unrestricted<br>£<br>-<br>457,128<br>30,249<br>16,584|£<br>-<br>-<br>-<br>-<br>Restricted|2024<br>Total<br>£<br>-<br>457,128<br>30,249<br>16,584|Unrestricted<br>£<br>(8,650)<br>306,961<br>-<br>1,500|£<br>-<br>-<br>-<br>-<br>Restricted|2023<br>Total<br>£<br>(8,650)<br>306,961<br>-<br>1,500|
||503,961|-|503,961|299,811|-|299,811|



*Repayment of excess/(distribution to) the parent charity under Gift Aid in 2023 

## 3 Income from charitable activites 

|Income from charitable activites|||||||
|---|---|---|---|---|---|---|
|Alliance - Scottish Grant<br>Lottery Community Funding - Scotland<br>Lottery Community Funding -  Wales<br>Section 10 Scottish Government<br>Intuitive Grant<br>Access Group Foundation Grant<br>Sense Foundation Grant<br>DHSC Grant<br>Blackbaud Grant<br>Bloomberg LP|Unrestricted<br>£<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-|£<br>-<br>42,103<br>56,486<br>24,367<br>-<br>-<br>20,337<br>86,331<br>-<br>53,000<br>Restricted|2024<br>Total<br>£<br>-<br>42,103<br>56,486<br>24,367<br>-<br>-<br>20,337<br>86,331<br>-<br>53,000|Unrestricted<br>£<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-|£<br>29,999<br>34,081<br>30,418<br>30,000<br>9,900<br>17,250<br>32,863<br>5,000<br>-<br>Restricted|2023<br>Total<br>£<br>29,999<br>34,081<br>30,418<br>-<br>30,000<br>9,900<br>17,250<br>32,863<br>5,000<br>-|
||-|282,624|282,624|-|189,511|189,511|



## 4 Income from other trading activities 

|Unrestricted<br>£<br>267,110<br>17,034<br>129,985|£<br>-<br>-<br>-<br>Restricted|2024<br>Total<br>£<br>267,110<br>17,034<br>129,985|Unrestricted<br>£<br>218,963<br>22,213<br>151,382|£<br>-<br>-<br>-<br>Restricted|2023<br>Total<br>£<br>218,963<br>22,213<br>151,382|
|---|---|---|---|---|---|
|414,129|-|414,129|392,558|-|392,558|



Other fundraising activities represent members and supporters raising funds on behalf of the charity. 

35 



Endometriosis UK 

## Notes to the financial statements 

## For the year ended 31 March 2024 

## 5a Analysis of expenditure (current year) 

## Charitable activities 

|Staff costs (Note 7)<br>Information<br>Membership EFE<br>Fundraising & Challenge Events<br>Office costs<br>Premises costs<br>Professional Fees<br>Helpline & Volunteer Expenses<br>Other costs<br>Support costs<br>Governance costs<br>Total expenditure 2024<br>Total expenditure 2023|Raising<br>funds<br>£<br>96,706<br>-<br>-<br>65,425<br>2,780<br>-<br>-<br>-<br>-<br>164,911<br>25,522<br>1,950<br>192,383<br>171,020|Helpline and<br>support<br>services<br>£<br>380,867<br> <br>-<br>174<br>-<br>50,890<br> <br>-<br> <br>-<br>86,578<br>4,015<br>522,524<br>99,962<br>7,638<br>630,124<br>422,844|Information<br>services<br>£<br>166,785<br>39,399<br>-<br> <br>-<br>56,063<br> <br>-<br> <br>-<br>-<br>3,778<br>266,025<br>43,601<br>3,331<br>312,957<br>168,602|Research<br>£<br>23,639<br>-<br> <br>-<br> <br>-<br>62<br> <br>-<br> <br>-<br> <br>-<br>-<br>23,701<br>6,381<br>488<br>30,569<br>25,056|Governance<br>costs<br>£<br>9,806<br> <br>-<br> <br>-<br> <br>-<br>1,320<br> <br>-<br>1,579<br> <br>-<br>702<br>13,407<br>-<br>(13,407)<br>-<br>-|Supports<br>Costs<br>£<br>14,044<br> <br>-<br> <br>-<br> <br>-<br>57,286<br> <br>44,134<br>54,823<br> <br>-<br>5,179<br>175,466<br>(175,466)<br>-<br>-|2024<br>Total<br>2023<br>Total<br>£<br>£<br>691,847<br>473,470<br>39,399<br>27,883<br>174<br>385<br>65,425<br>48,545<br>168,401<br>120,477<br>44,134<br>40,522<br>56,402<br>48,427<br>86,578<br>17,556<br>13,674<br>10,256<br>1,166,034<br>787,521<br>-<br>-<br>-<br>-<br>1,166,034<br>787,521|
|---|---|---|---|---|---|---|---|
|||||||-||



36 



Endometriosis UK 

## Notes to the financial statements 

## For the year ended 31 March 2024 

## 5b Analysis of expenditure (previous year) 

## Charitable activities 

|Staff costs (Note 7)<br>Information<br>Membership EFE<br>Fundraising & Challenge Events<br>Office costs<br>Premises costs<br>Professional Fees<br>Helpline & Volunteer Expenses<br>Other costs<br>Support costs<br>Governance costs<br>Total expenditure 2023|Raising<br>funds<br>£<br>78,338<br>-<br>-<br>48,545<br>13,585<br>-<br>-<br>-<br>2,552<br>143,020<br>23,195<br>4,804<br>171,020|Helpline and<br>support<br>services<br>£<br>251,399<br>-<br>385<br>-<br>62,578<br>-<br>-<br>17,556<br>2,552<br>334,470<br>73,210<br>15,164<br>422,844|Information<br>services<br>£<br>89,657<br>27,883<br>-<br>-<br>18,687<br>-<br>-<br>-<br>-<br>136,227<br>26,820<br>5,555<br>168,602|Research<br>£<br>8,933<br>-<br>-<br>-<br>3,873<br>-<br>-<br>-<br>-<br>12,806<br>10,148<br>2,102<br>25,056|Governance<br>costs<br>£<br>14,271<br>-<br>-<br>-<br>3,176<br>-<br>7,850<br>-<br>2,328<br>27,625<br>-<br>(27,625)<br>-|Supports<br>Costs<br>2023<br>Total<br>£<br>£<br>30,872<br>473,470<br>-<br>27,883<br>-<br>385<br>-<br>48,545<br>18,578<br>120,477<br>40,522<br>40,522<br>40,577<br>48,427<br>-<br>17,556<br>2,824<br>10,256<br>133,373<br>787,521<br>(133,373)<br>-<br>-<br>-<br>-<br>787,521|
|---|---|---|---|---|---|---|



37 



Endometriosis UK 

## Notes to the financial statements 

## For the year ended 31 March 2024 

- 6 Net income for the year 

This is stated after charging / (crediting): 

|This is stated after charging / (crediting):|||
|---|---|---|
||2024|2023|
||£|£|
|Depreciation|12,543|7,656|
|Operating lease rentals payable:|||
|Property|48,772|30,174|
|Other|-|886|
|Auditor's remuneration (excluding VAT):|||
|Audit|8,400|7,850|
|Other services|1,360|990|



- 7 Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel 

Staff costs were as follows: 

|Staff costs were as follows:|||
|---|---|---|
|Salaries and wages<br>Social security costs<br>Employer’s contribution to defined contribution pension schemes|2024<br>£<br>613,579<br>56,426<br>21,842|2023<br>£<br>425,256<br>37,541<br>10,673|
||691,847|473,470|



No employee earned more than £60,000 during the year (2023: nil). 

The total employee benefits (including pension contributions and employer's national insurance) of the key management personnel were £60,507 (2023: £50,384). 

The charity trustees were neither paid nor received any other benefits from employment with the charity in the year (2023: £nil).  No charity trustee received payment for professional or other services supplied to the charity (2023: £nil). 

Trustee expenses represents the payment or reimbursement of travel and subsistence costs totalling £564 (2023: £88) incurred by one (2023: 1) member relating to attendance at meetings of the trustees. 

## 8 Staff numbers 

The average number of employees (head count based on number of staff employed) during the year was 17 (2023: 14.5). 

11 employees worked full time, with 9 employees working part time. The CEO is part time, 3 or 4 days per week. 

Staff are split across the activities of the charity as follows (full time equivalent basis): 

|Staff are split across the activities of the charity as follows (full time equivalent basis):|||
|---|---|---|
|Helpline and support services<br>Research<br>Governance<br>Raising funds<br>Information services|2024<br>No.<br>2.4<br>9.4<br>4.1<br>0.6<br>0.5|2023<br>No.<br>3.2<br>10.1<br>3.7<br>1.4<br>0.6|
||17.0|19.0|



## 9 Related party transactions 

Endometriosis UK received donations totalling £860 (2023:£320) from 4 trustees (2023: 11). The trustees receive no benefit from the donations made to the charity. 

During the financial year there were no related party transactons. 

38 



Endometriosis UK 

Notes to the financial statements 

## For the year ended 31 March 2024 

## 10 Subsidiary undertaking 

Endometriosis UK Trading Limited was incorporated in the UK as a wholly owned subsidiary of Endometriosis UK on 2 June 2006 (Company No: 05836007), with an issued share capital of £1.  The trading company is not consolidated within these financial statements as the level of the activity is not material to the group. 

A summary of the results of the subsidiary is shown below: 

|A summary of the results of the subsidiary is shown below:|||
|---|---|---|
|Profit/(loss) on ordinary activities before interest and taxation<br>Total comprehensive income<br>Retained earnings<br>The aggregate of the assets, liabilities and reserves was:<br>Assets<br>Liabilities<br>Reserves<br>Total retained earnings brought forward<br>Total comprehensive income<br>Distribution under Gift Aid to parent charity<br>Total retained earnings carried forward<br>Turnover<br>Taxation on profit on ordinary activities<br>Gross profit/(loss)<br>Administrative expenses|2024<br>£<br>3|2023<br>£<br>7|
||3<br>(1,035)|7<br>(8,142)|
||(1,032)<br>-|(8,135)<br>-|
||(1,032)|(8,135)|
||2,875<br>(1,032)<br>-|(4,754)<br>(8,135)<br>15,764|
||1,843|2,875|
||1,843<br>-|2,875<br>-|
||1,843|2,875|



## 11 Taxation 

The charity is exempt from corporation tax as all its income is charitable and is applied for charitable purposes. 

## 12 Tangible fixed assets 

|Tangible fixed assets|||
|---|---|---|
|At the start of the year<br>At the end of the year<br>Additions in year<br>Depreciation<br>At the end of the year<br>At the start of the year<br>Charge for the year<br>At the end of the year<br>At the start of the year<br>Cost<br>Net book value|Office<br>equipment<br>£<br>56,458<br>8,947|Total<br>£<br>56,458<br>8,947|
||65,405|65,405|
||18,445<br>12,543|18,445<br>12,543|
||30,988|30,988|
||34,417|34,417|
||38,013|38,013|



All of the above assets are used for charitable purposes. 

39 



Endometriosis UK 

## Notes to the financial statements 

## For the year ended 31 March 2024 

- 13 Debtors 

|Debtors|||
|---|---|---|
|Other debtors<br>Other creditors<br>Accruals<br>Taxation and social security<br>Amounts due to subsidiary<br>Creditors: amounts falling due within one year<br>Prepayments<br>Accrued income|2024<br>£<br>2,396<br>13,339<br>23,970|2023<br>£<br>9,975<br>53,502<br>12,615|
||39,705|76,092|
||2024<br>£<br>21,181<br>61,125<br>11,965<br>213|2023<br>£<br>17,775<br>17,186<br>15,121<br>1,383|
||94,484|51,465|



- 14 Creditors: amounts falling due within one year 

15a Analysis of net assets between funds (current year) 

|Analysis of net assets between funds (current year)|||||
|---|---|---|---|---|
|Net current assets<br>Net assets at 31 March 2024<br>Analysis of net assets between funds (prior year)<br>Tangible fixed assets<br>Net assets at 31 March 2023<br>Tangible fixed assets<br>Net current assets|General<br>unrestricted<br>£<br>34,417<br>982,644|Restricted<br>£<br>-<br>97,404|Designated<br>Funds<br>-<br>238,000|Total funds<br>£<br>34,417<br>1,318,047|
||1,017,060|97,404|238,000|1,352,464|
||General<br>unrestricted<br>£<br>38,013<br>827,592|Restricted<br>£<br>-<br>97,166|Designated<br>Funds<br>-<br>336,000|Total funds<br>£<br>38,013<br>1,260,758|
||865,605|97,166|336,000|1,298,771|



15b Analysis of net assets between funds (prior year) 

40 



Endometriosis UK 

## Notes to the financial statements 

## For the year ended 31 March 2024 

## 16a Movements in funds (current year) 

|Lottery Community Funding -  Wales<br>Intuitive Grant<br>Access Group Foundation Grant<br>Sense Foundation Grant<br>DHSC Grant<br>Blackbaud Grant<br>Section 10 Scottish Government<br>Bloomberg LP<br>Total restricted funds<br>Total designated funds<br>General funds<br>Total funds<br>Total unrestricted funds<br>Unrestricted funds:<br>Designated funds:<br>Webchat and Helpline expansion<br>Restricted funds:<br>Lottery Community Funding - Scotland<br>Additional Scottish Project<br>Diversity & Inclusion activities<br>Alliance - Scottish Grant|At 1 April 2023<br>£<br>9,971<br>23,111<br>29,994<br>6,800<br>5,637<br>17,250<br>-<br>4,403|Income and<br>gains<br>£<br>-<br>42,103<br>56,486<br>-<br>-<br>20,337<br>86,331<br>-<br>24,367<br>53,000|Expenditure<br>and losses<br>£<br>(9,971)<br>(45,700)<br>(50,249)<br>(6,800)<br>(5,637)<br>(23,783)<br>(86,331)<br>(4,403)<br>(24,367)<br>(25,145)|Transfers<br>£<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-|At 31 March<br>2024<br>£<br>-<br>19,514<br>36,231<br>-<br>-<br>13,804<br>-<br>-<br>-<br>27,855|
|---|---|---|---|---|---|
||97,166|282,624|(282,386)|-|97,404|
||140,000<br>40,000<br>156,000|-<br>-<br>-|(46,000)<br>-<br>(52,000)|-<br>-<br>-|94,000<br>40,000<br>104,000|
||336,000|-|(98,000)|-|238,000|
||865,605|937,103|(785,648)|-|1,017,060|
||1,201,605|937,103|(883,648)|-|1,255,060|
||1,298,771|1,219,727|(1,166,034)|-|1,352,464|



The narrative to explain the purpose of each fund is given at the foot of the note below. 

16b Movements in funds (prior year) 

|Lottery Community Funding -  Wales<br>Intuitive Grant<br>Access Group Foundation Grant<br>Sense Foundation Grant<br>DHSC Grant<br>Blackbaud Grant<br>Total restricted funds<br>Total designated funds<br>General funds<br>Total funds<br>Alliance - Scottish Grant<br>Unrestricted funds:<br>Designated funds:<br>Webchat and Helpline expansion<br>Additional Scottish Project<br>Diversity & Inclusion activities<br>Lottery Community Funding - Scotland<br>Total unrestricted funds<br>Restricted funds:<br>Takeda|At 31 March<br>2022<br>£<br>10,050<br>14,607<br>27,106<br>-<br>-<br>-<br>-<br>-<br>-|Income and<br>gains<br>£<br>-<br>29,999<br>34,081<br>30,418<br>30,000<br>9,900<br>17,250<br>32,863<br>5,000|Expenditure<br>and losses<br>£<br>(10,050)<br>(34,635)<br>(38,076)<br>(424)<br>(23,200)<br>(4,263)<br>-<br>(32,863)<br>(597)|Transfers<br>£<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-|At 1 April<br>2023<br>£<br>-<br>9,971<br>23,111<br>29,994<br>6,800<br>5,637<br>17,250<br>-<br>4,403|
|---|---|---|---|---|---|
||51,763|189,511|(144,108)|-|97,166|
||140,000<br>40,000<br>36,000|-<br>-<br>-|-<br>-<br>-|-<br>-<br>120,000|140,000<br>40,000<br>156,000|
||216,000|-|-|120,000|336,000|
||923,959|705,059|(643,413)|(120,000)|865,605|
||1,139,959|705,059|(643,413)|-|1,201,605|
||1,191,722|894,570|(787,521)|-|1,298,771|
||||||~~41~~|





Endometriosis UK 

Notes to the financial statements 

## For the year ended 31 March 2024 

## 16 Movements in funds (continued) 

## Purpose of restricted funds 

Restricted funds represent donations and grants restricted for use on particular areas of the charity's work. 

## Lottery Community Funding  - Scotland 

The National Lottery Community Fund provided a grant to support 

- Expanding and strengthening Support Groups in Scotland 

- Increasing the awareness and availability of our Helpline, WebChat and information resources 

- Appointing a Scotland-based staff member to deliver the above 

## Lottery Community Funding  - Wales 

The National Lottery Community Fund provided a grant to support 

- Expanding and strengthening Support Groups in Wales 

- Increasing the awareness and availability of our Helpline, WebChat and information resources 

- Appointing a Wales based staff member to deliver the above 

## Intuitive Grant 

Intuitive Grant developing information resources on endometriosis surgery 

- Developing video content with specilialist surgeons and patients 

- Producing online and printable leaflets to include RAS and laparoscopy. 

## The Access Foundation Grant 

Funding for web Chat, Helpline and Information 

- Funding towards the develoment of information 

- Funding towards the costs of the helpline and web chat 

## SENSE Foundation Brussels Grant 

Support and Information project 

- Recruting and training helpline and web chat volunteers 

- Reviewing and developing information 

- Increasing helpline and webchat provision 

## DHSC Grant 

DHSC Grant to develop a workplace menstrual wellbeing programme 

- Developing and providing information and guidance on a range of menstrual conditions to SME's 

- Providing SME's with targeted information events, webinars, resources and downloadable information 

## Blackbaud Grant 

Funds towards the Endometriosis UK Helpline and webchat 

- Funds towards the Endometriosis UK Helpline and webchat 

## Section 10 Scottish Government 

Support & Information Project 

- Improve access and to deliver information around pain for women with endometriosis 

## Bloomberg LP 

EDI Projects in London 

- To deliver over 3 years awareness & understanding of Endometriosis to various EDI communities 

## Purpose of designated funds 

## Webchat and Helpline expansion 

To fund the ongoing support, development and expansion for a webchat and helpline services  over the three years. 

## Additional Scottish Project 

This is in addition to the grant funding received allowing us to undertake additional activities in Scotland and will be spent over the next three years. 

## Additional Diversity and Inclusion activities 

We had identified that we had less reach within certain communities, notably those from black, Asian and minority ethnic and LGBTQ+ community. Additional funding has been allocated, to increase capacity in this area, undertake research and deliver improved reach over the next three years. 

42 



Endometriosis UK 

Notes to the financial statements 

## For the year ended 31 March 2024 

- 17 Operating lease commitments payable as a lessee 

The charity's total future minimum lease payments under non-cancellable operating leases is as follows for each of the following periods 

|following periods|||||
|---|---|---|---|---|
|Less than one year -  Mutual 3 month break clause|2024<br>2023<br>£<br>£<br>7,508<br>7,508<br>7,508<br>7,508<br>Property||2024<br>2023<br>£<br>£<br>-<br>-<br>-<br>-<br>Other||
||7,508|7,508|-|-|



- 18 Legal status of the charity 

The charity is a company limited by guarantee and has no share capital.  The liability of each member in the event of winding up is limited to £1. 

43